Immunic Inc. Stock
Price
Target price
€0.60
€0.60
0.330%
0.002
0.330%
€8.89
26.06.25 / Tradegate
WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Financial data and news for Immunic
sharewise wants to provide you with the best news and tools for Immunic, so we directly link to the best financial data sources.
Financials
News
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
EQS-News: Immunic to Participate in Scientific and Investor Conferences in March
EQS-News: Immunic to Participate in Scientific and Investor Conferences in March
EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
EQS-News: Immunic to Participate in Investor and Scientific Conferences in February
EQS-News: Immunic to Participate in Investor and Scientific Conferences in February
EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones